Fischl M - Search Results

1

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B. Pollard RB, et al. Among authors: fischl m. Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11. Lancet Infect Dis. 2014. PMID: 24525316 Clinical Trial.

2

The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals.

Bass HZ, Hardy WD, Mitsuyasu RT, Taylor JM, Wang YX, Fischl MA, Spector SA, Richman DD, Fahey JL. Bass HZ, et al. Among authors: fischl ma. J Acquir Immune Defic Syndr (1988). 1992;5(3):215-21. J Acquir Immune Defic Syndr (1988). 1992. PMID: 1346807 Clinical Trial.

3

The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, Hardy WD, Dolin R, Powderly WG, Allan JD, et al. Fischl MA, et al. Ann Intern Med. 1990 May 15;112(10):727-37. doi: 10.7326/0003-4819-112-10-727. Ann Intern Med. 1990. PMID: 1970466 Clinical Trial.

4

HIV-1 inhibition by azidothymidine in a concurrently randomized placebo-controlled trail.

Parks WP, Parks ES, Fischl MA, Leuther MD, Allain JP, Nusinoff-Lehrman S, Barry DW, Makuch RW. Parks WP, et al. Among authors: fischl ma. J Acquir Immune Defic Syndr (1988). 1988;1(2):125-30. J Acquir Immune Defic Syndr (1988). 1988. PMID: 3145972 Clinical Trial.

5

Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.

Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, Brown MJ, Cross AP, Hirsch MS, Hardy WD, et al. Dolin R, et al. Among authors: fischl ma. Arch Intern Med. 1995 May 8;155(9):961-74. Arch Intern Med. 1995. PMID: 7726705 Clinical Trial.

6

The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.

Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC Jr, Fass RJ, Fife KH, Powderly WG, Collier AC, Aspinall RL, et al. Fischl MA, et al. J Acquir Immune Defic Syndr (1988). 1994 Feb;7(2):139-47. J Acquir Immune Defic Syndr (1988). 1994. PMID: 7905523 Clinical Trial.

7

Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.

Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC, Powderly WG. Fischl MA, et al. Ann Intern Med. 1995 Jan 1;122(1):24-32. doi: 10.7326/0003-4819-122-1-199501010-00004. Ann Intern Med. 1995. PMID: 7985892 Clinical Trial.

8

Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group.

Fischl MA, Krown SE, O'Boyle KP, Mitsuyasu R, Miles S, Wernz JC, Volberding PA, Kahn J, Groopman JE, Feinberg J, et al. Fischl MA, et al. J Acquir Immune Defic Syndr (1988). 1993 Mar;6(3):259-64. J Acquir Immune Defic Syndr (1988). 1993. PMID: 8450401 Clinical Trial.

9

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS. D'Aquila RT, et al. Among authors: fischl ma. Ann Intern Med. 1996 Jun 15;124(12):1019-30. doi: 10.7326/0003-4819-124-12-199606150-00001. Ann Intern Med. 1996. PMID: 8633815 Clinical Trial.

10

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.

Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. Welles SL, et al. Among authors: fischl m. J Infect Dis. 1996 Oct;174(4):696-703. doi: 10.1093/infdis/174.4.696. J Infect Dis. 1996. PMID: 8843205

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

341 results

Search Page